Tumor budding in primary pancreatic adenocarcinoma

This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.

Tumor budding (BT) is an emerging prognostic factor in several cancers, including pancreatic cancer. Our bi-centric study (2008-2022) aimed to evaluate BT by morphological method and with QUPATH software, and to analyze its impact on overall and event-free survival. We included 25 cases of pancreatic adenocarcinoma, with a mean age of 62 years and a male predominance (72%). BT was detected in 100% of cases morphologically and 80% by QUPATH. A high BT (BUD2/BUD3) was found in 56% of cases morphologically and 48% by QUPATH, with no significant difference between methods (p=0.589). A high BT was associated with advanced age (p=0.03) and negatively influenced overall survival (p=0.038). This study suggests that BT is a key prognostic factor and that QUPATH could become an accessible tool for standardizing its assessment in pathology.